Alpha Corifolitropin is the major component of the Elonva drug in the Schering-Plow laboratory.
Treatment with Elonva should be initiated under the supervision of a physician experienced in the treatment of fertility problems (pregnancy difficulties). It is available in injection solution of 100 mcg / 0.5 mL and 150 mcg / 0.5 mL (pack with 1 filled syringe and a separate needle)
Indications of Elonva
Controlled Ovarian Stimulation (EOC) for the development of multiple follicles and pregnancy in women participating in Assisted Reproductive Technology (ART) program.
Price Elonva
The value of Alfa Corifolitropin (ELONVA), can range from approximately 1, 800 to 2, 800 reais.
Contraindications of Elonva
Alfa corifolitropin, the active ingredient of Elonva, is contraindicated in patients who exhibit hypersensitivity (allergy) to the active substance or to any of the excipients of the product formulation, patients with ovarian, breast, uterine, pituitary or hypothalamic tumors, abnormal vaginal bleeding (no menstrual period) with no known and diagnosed cause, primary ovarian failure, ovarian cysts or increased ovaries, a history of ovarian hyperstimulation syndrome (SHEO), a previous EOC cycle that resulted in more than 30 follicles greater than or equal to 11 mm shown by ultrasound examination, an initial count of antral follicles greater than 20, fibrous tumors of the uterus incompatible with pregnancy, malformations of reproductive organs incompatible with pregnancy.
This medication is not indicated for pregnant women, or who suspect they may be pregnant, or are breast feeding.
Side effects of Elonva
The most frequently reported adverse events are ovarian hyperstimulation syndrome, pelvic pain, discomfort, headache, nausea (tiredness), fatigue (tiredness) and breast complaints (including increased breast tenderness), among others.
How to use Elonva
The recommended dose for women with body weight greater than or equal to 60 kg is 100 mcg in single injection and for women weighing more than 60 kg, the recommended dose is 150 mcg in a single injection.
Elonva (alfacorifolitropin) should be given as a single injection subcutaneously, preferably into the abdominal wall, during the initial follicular phase of the menstrual cycle.
Elonva (alfacorifolitropina) is exclusively intended for single injection by the subcutaneous route. Additional injections of Elonva (alfacorifolitropina) should not be done within the same course of treatment.
The injection should be given by a health care provider (eg a nurse), either by the patient himself or by his partner, as long as they are told by the doctor.
